22 investigations have been conducted and published on COVID-19 and ozone therapy, of which 13 (59%) are on MedLine (PubMed).

The main results of the studies indicate that ozone decreases the inflammation indices and the time of assisted breathing, improves oxygen saturation and makes CRP negative in shorter periods. Increases oxygen saturation. And it could reduce mortality.

The total number of patients treated in the different investigations, including prevention studies, post-COVID studies and with COVID-19 patients has been 721. The routes of application have been ozonized saline solution, major autohemotherapy, and rectal insufflation.

Ozone therapy research, beyond COVID-19, continues to advance.

Information compiled by Dr. Gregorio Martínez, member of AEPROMO and president of ISCO3

Currently (May 31, 2021) in the Medline database (PubMed) there are 3329 documents related to ozone therapy of which 251 are clinical trials, 169 randomized controlled trials, 24 of systematic review and 18 meta-analysis studies, which support the use of ozone in medicine. In addition, there are 37 registered studies for ozone therapy on ClinicalTrials.gov (database of clinical trials at the US National Institutes of Health).

The WHO (World Health Organization) has published in its virtual library “COVID-19 – Global literature on coronavirus disease” three following investigations on Ozonized Saline Solution and COVID-19.

(1) Complementary application of the ozonized saline solution in mild and severe patients with pneumonia COVID-19: A non-randomized pilot study. Schwartz, Adriana. et al. https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-984802. Acces to full paper  https://jppres.com/jppres/pdf/vol9/jppres20.971_9.2.126.pdf

(2) Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2 / COVID-19. Martínez-Sánchez, G. Schwartz A. et al.

This content is also available in: Spanish